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Abstract
Background: About 5-10% of breast cancer is due to inherited disease predisposition. Many
previously identified susceptibility factors are involved in the maintenance of genomic integrity.
AATF plays an important role in the regulation of gene transcription and cell proliferation. It
induces apoptosis by associating with p53. The checkpoint kinases ATM/ATR and CHEK2 interact
with and phosphorylate AATF, enhancing its accumulation and stability. Based on its biological
function, and direct interaction with several known breast cancer risk factors, AATF is a good
candidate gene for being involved in heritable cancer susceptibility.
Methods: Here we have screened the entire coding region of AATF in affected index cases from
121 Finnish cancer families for germline defects, using conformation sensitive gel electrophoresis
and direct sequencing.
Results: Altogether seven different sequence changes were observed, one missense variant and
six intronic ones. Based on the in silico analyses of these sequence alterations, as well as their
occurrence in cases and controls, none of them, however, were predicted to be pathogenic.
Conclusions: To our knowledge, this is the first study reporting the mutation screening of the
AATF gene in familial breast cancer cases. No evidence for the association with breast cancer was
observed.
Background
In most Western populations, about one in ten women
develop breast cancer [1]. Approximately 5-10% of these
cases are considered to be familial [2]. Mutations in two
major high penetrance genes BRCA1 and BRCA2 are well
known, but they seem to be responsible for less than 20%
of heritable disease predisposition [3,4]. Only a small
number of the familial cases are explained by mutations
in other known cancer susceptibility genes, such as TP53,
PTEN, ATM, CHEK2, NBS1, RAD50, BRIP1 and PALB2
[5,6]. The identification of additional genes involved in
breast cancer predisposition is complicated by genetic het-
erogeneity. The remaining cases could be the result of a
few additional, yet unidentified, high penetrance muta-
tions, but the polygenic model may provide a more plau-
sible explanation [7]. Recent genome-wide association
studies have identified a few common low penetrance
breast cancer susceptibility alleles. Together these loci are,
however, estimated to account less than 4% of the familial
risk of breast cancer in European populations [1]. As most
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of the known breast cancer susceptibility genes are
involved in DNA damage response pathways, other genes
involved in these essential and highly complex and multi-
layered processes represent excellent candidates for iden-
tifying further cancer predisposing alleles.
AATF (apoptosis antagonizing transcription factor, also
know as CHE1) was originally characterized as an inter-
acting protein for RNA polymerase II. The AATF gene is
located at chromosome 17q11.2-q12. It encodes a phos-
phoprotein containing 558 amino acids [8] and consists
of 12 exons. The protein is highly conserved among
eukaryotic species during evolution [9]. AATF does not
display homology to any previously described protein. It
contains a leucine zipper motif, several phosphorylation
sites for different kinases, a nuclear localization signal
motif, three nuclear receptor LXXLL binding motifs and
several four nucleotide repeats (Figure 1) [9,10]. The func-
tions of AATF are essential during the early stages of
embryogenesis and cell proliferation [11,12]. One signifi-
cant function of AATF is to promote cellular transcription,
acting as an adaptor that links specific transcription fac-
tors to the general transcription apparatus. Furthermore,
due to its interaction with various important components
of the cell survival machinery, AATF has been found to
play an important role in DNA damage response, cell-
cycle checkpoint control, apoptosis and also in chromatin
remodeling [13]. Interestingly, AATF operates in a dualis-
tic way, showing both inhibitory and stimulatory roles in
regard to cell-cycle progression and cell proliferation [10].
AATF is also a nuclear receptor co-activator and regulates
the physiological effect of p53. The p53 protein plays a
critical role in the cellular response to DNA damage and
other stresses by inhibiting proliferation or by inducing
apoptosis [14]. Upon DNA damage, AATF is phospor-
ylated by ATM and CHEK2, consequently increasing its
stability and accumulation to the cell nucleus, but also
enhancing p53 expression and G2-M arrest [10,15].
Although AATF induces apoptosis by associating with
p53, it also has an antagonistic role in several cell types,
acting as an inhibitor of apoptosis [10]. Its function as
transcription factor or as co-activator has not yet been
fully worked out. However, there seem to be different
modes by which AATF cooperates with other transcription
factors [16]. Based on all these observations it is reasona-
ble to speculate that AATF may be a component of the
checkpoint anticancer barrier that protects cells from DNA
damage or oncogenic stress. Furthermore, AATF has been
found to be down-regulated in several colon carcinomas
and is involved in growth arrest through induction of p21
[17].
Based on its biological function, we wanted to determine
whether AATF germline mutations are involved in hered-
itary susceptibility to breast cancer. We have, therefore,
screened the entire coding sequence and exon-intron
boundaries of the gene in Finnish cancer families. AATF
sequence alterations have not previously been studied in
relation to breast cancer predisposition.
Methods
Cases and controls
Breast and breast-ovarian cancer families (N = 121) origi-
nating in northern Finland were selected for the screening
of possible germline mutations in AATF. Inclusion criteria
for the 70 (58%) families classified as high-risk ones were
the following: 1) three or more cases of breast, or breast
and ovarian cancer in first- or second-degree relatives, or
2) two cases of breast, or breast and ovarian cancer in first-
or second-degree relatives, of which at least one with early
disease onset (≤ 35 years), bilateral disease or multiple
primary tumors, including breast cancer in the same indi-
vidual. Most of the high-risk families had three or more
cases. The remaining 51 (42%) families with moderate
disease susceptibility displayed two cases of breast cancer
Schematic diagram of AATF protein structure and location of observed missense variant Figure 1
Schematic diagram of AATF protein structure and location of observed missense variant. Structure and main 
functional domains of AATF are shown. Leucine zipper motif location (aa 275-296) is marked in dark grey, with the basic 
domain in horizontal stripes (aa 133-145). Nuclear translocation signal is shown in diagonal stripes (aa 338-344). Three nuclear 
receptor binding motifs are marked in light grey (aa 11-15, 281-285, 520-524). The location of the observed amino acid altera-
tion is shown by an arrow (functional domain structure modified mainly from reference [9]).
1
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in first- or second-degree relatives. All high-risk families
were previously screened for germline mutations in
known or potential susceptibility genes BRCA1, BRCA2,
CHEK2, TP53, RAD50, RAP80 or PALB2 [6,18-22], and
disease associated alterations in these genes were seen in
altogether 17 of the families. These mutation-positive
families were included in the current study because we did
not want to rule out potential genetic modifier effects. The
frequency of all observed germline variants were deter-
mined in control samples (N ≥ 307) obtained from anon-
ymous cancer-free female Finnish Red-Cross blood
donors originating in the same geographical region as the
studied families. All patients had given their informed
consent for obtaining pedigree data and blood specimens
for the study of cancer susceptibility gene mutations. An
approval to perform the study was obtained from the Eth-
ical Board of the Northern Ostrobothnia Health Care Dis-
trict and the Finnish Ministry of Social Affairs and Health.
DNA isolation and mutation analysis
DNA was extracted from blood lymphocytes using the
standard phenol-chloroform method or the Purgene D-50
K purification kit (Gentra, Minneapolis, USA). The entire
coding region and exon-intron boundaries of the AATF
gene were screened for germline mutations by conforma-
tion sensitive gel electrophoresis (CSGE) [23]. Samples
with band shifts were reamplified and the sequencing
analysis was performed on a Li-Cor IR2 4200-S DNA Anal-
ysis system (Li-Cor Inc., Lincoln, USA) using the
SequiTherm EXEL TM II DNA Sequencing Kit-LC (Epicen-
tre Technologies, Madison, USA). Oligonucleotides for
CSGE and sequencing were designed using the Primer3
software based on sequence information obtained from
public databases (Genomic sequence NC_000017.9,
mRNA NM_012138.3). Primers and PCR conditions for
mutation screening and sequencing are available upon
request.
Statistical and bioinformatic methods
Carrier frequencies were compared by using Pearson's χ2
or Fisher's exact test with SPSS version 16.0 for Windows
(SPSS Inc., Chicago, USA). All P-values were two-sided.
The missense alteration c.739G>T (p.Ala247Ser) was
tested for possible pathogenicity by using PolyPhen soft-
ware. ESEfinder software was applied to determine if the
exonic variant was located in an ESE (exonic splicing
enchancer) sequence and might, therefore, affect the ESE
function. All alterations were also checked for potential
splicing effects with NNSplice software.
Results
The study of 121 breast or breast-ovarian cancer families
revealed altogether seven different germline changes in
the  AATF  gene (Table 1). Only one of the observed
changes was exonic. This novel alteration resulted in an
Ala247Ser amino acid substitution in the protein product.
All the other seen variants were intronic. In order to eval-
uate possible pathogenicity of the observed changes, their
frequencies were compared between cases and healthy
control individuals. Assessment of the consequences of
the observed changes was also done by using PolyPhen,
ESEfinder and NNSplice software.
The p.Ala247Ser alteration was observed in 1.7% (2/121)
of the patients and 1.3% (4/317) of the controls (P = 0.7).
These two amino acids display very different characteris-
tics. Alanine is a small hydrophobic and aliphatic amino
acid, whereas serine is a polaric and hydrophilic residue.
Based on the analysis using PolyPhen software the effect
of this change, however, was predicted to be neutral. Nei-
ther had any influence on splicing nor ESE functions indi-
cated.
All six intronic alterations observed were single nucleotide
changes, four of which were novel ones, whereas two had
already been described earlier in the internet-based
sequence variation database http://
www.ncbi.nlm.nih.gov/projects/SNP/. Most of the altera-
tions were present in cases and controls at similar frequen-
cies. However, one of the variants, c.832+17C>T, was only
found among cases 0.8% (1/123) but not in controls (0/
317). Furthermore, one alteration, c.1619+29A>C,
Table 1: Observed germline alterations in the AATF gene in Finnish breast cancer families
Carrier frequencya (%)
Exon/Intron Nucleotide change Effect on protein Familial cases Controls P-value
(OR, 95% CI)
Previously known (+) or 
unknown (-) alteration
Ex 4 c.739G>T p.Ala247Ser 1.7 (2/121) 1.3 (4/317) 0.70 (1.3, 0.2-7.1) -
Int 3 c.694+35A>C None 4.1 (5/121) 9.1 (30/328) 0.08 (0.4, 0.2-1.1) +; RS: 8067751
c.694+48T>G None 3.3 (4/121) 0.9 (3/328) 0.09 (3.7, 0.8-16.8) -
Int 4 c.832+17C>T None 0.8 (1/121) 0.3 (1/317) 0.48 (2.6, 0.16-42.4) -
c.832+39C>T None 0.8 (1/121) - (0/317) 0.28 (NA) -
Int 11 c.1619+29A>C None 2.5 (3/121) 0.3 (1/325) 0.06 (8.2, 0.8-80.0) -
Int 12 c.1670+42C>T None 20.7 (25/121) 23.5 (72/307) 0.53 (0.9, 0.5-1.4) +; RS:11653434
NA, not available; OR, odds ratio; CI, confidence interval; aHeterozygotesBMC Cancer 2009, 9:457 http://www.biomedcentral.com/1471-2407/9/457
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occurred more frequently among cases 2.5% (3/121) than
in controls 0.3% (1/324), but nevertheless the difference
was not statistically significant (P = 0.066). According to
the analysis using NNSplice software, none of the intronic
changes observed had any effect on splicing.
Discussion
The aim of our study was to determine the relationship
between breast cancer susceptibility and potential altera-
tions in the AATF candidate gene, which plays an impor-
tant role in the maintenance of genomic integrity and cell-
cycle checkpoint control [10]. Because of its influence on
vital cellular functions it was considered possible that
mutations in the AATF gene might contribute to heredi-
tary disposition to breast cancer.
In the current study, the whole coding region of the AATF
gene was systematically screened for mutations in 121
breast cancer families. We found several sequence variants
in the AATF gene: one exonic and six intronic ones. The
observed exonic change c.739G>T (p.Ala247Ser) was a
novel one, but it located outside the functionally impor-
tant domains. Furthermore, none of the intronic changes
seemed to affect consensus splicing sequences. All
observed variants displayed similar allele frequencies in
cases and controls. Consequently, none of the observed
alterations seemed to associate with an increased cancer
risk. The absence of deleterious germline mutations in the
AAFT gene could indicate conserved and essential func-
tion of the protein in cell cycle control and DNA damage
response. However, a small study like this cannot exclude
the possibility of rare mutations in AATF that might pre-
dispose to breast cancer, but based on our findings, they
unlikely make any sizeable contribution to cancer predis-
position.
Conclusions
The observed AATF  gene alterations lacked association
with breast cancer risk and therefore mutations in this
gene are likely not to play a significant role in hereditary
predisposition to this malignancy. To our knowledge, this
is the first investigation reporting the mutation screening
of the AATF gene in familial breast cancer cases.
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